Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

TransCode Therapeutics, Inc. - Common Stock (NQ: RNAZ )

3.350 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about TransCode Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138
TTX-MC138 is Effective in Animal Models of Human Metastatic Pancreatic Cancer 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Withdraws Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Public Offering of Common Stock
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138
Suggests potential to improve survival outcomes in patients with GBM 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138
Evidence of Drug Accumulation in Metastatic Lesions 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA
Study showed a 70% Inhibition of Recurrent Tumor Growth 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Closing of $8.5 Million Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Pricing of $8 Million Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138
Further Supports TTX-MC138 Application in Brain Cancer 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:VACC),(NASDAQ:BPTS),(NASDAQ:RNAZ),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
TransCode Therapeutics Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial
Designed to demonstrate delivery of TTX-MC138 to metastatic lesions 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Reports Second Quarter 2023 Results; Provides Business Update
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Positive Results in Non-human Primates with its Lead Therapeutic Candidate, TTX-MC138
Further Supporting TTX-MC138 Application in Metastatic Cancer 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Stonegate Healthcare Partners Announces Publishing of a Thematic Report - The RNA Revolution: Unleashing the Therapeutic Potential of RNAi
Dallas, Texas--(Newsfile Corp. - July 13, 2023) - Stonegate Healthcare Partners (SHP), a healthcare strategy consulting firm, is pleased to... 
Via Newsfile
TransCode Therapeutics CEO Letter to Shareholders
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Publication of New Data Supporting the Use of TTX-MC138 for the Treatment of Metastatic Breast Cancer
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Closing of $7 Million Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Pricing of $7 Million Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Glioblastoma
Study provides support for further evaluation of TransCode’s lead therapeutic candidate, TTX-MC138, in clinical trials 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces 1-for-20 Reverse Stock Split
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Strategic Expansion of its Product Portfolio
Submits Provisional Patent Application entitled “Nanoparticles Comprising Payloads and Their In Vivo Delivery.” 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Equity Investment from White Lion Capital to Help Fund Development of TTX-MC138 for Treatment of Glioblastomas
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics to present at AACR Annual Meeting 2023
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Receives Notice of Award from National Institutes of Health (NIH) for Third Year of Grant to Support Clinical Evaluation of TTX-MC138
From TransCode Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.